Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$67.23 USD

67.23
11,849,108

-2.13 (-3.07%)

Updated Sep 17, 2024 04:00 PM ET

After-Market: $67.23 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

STERIS' (STE) Q2 Earnings Surpass Estimates, FY20 View Up

STERIS (STE) witnesses solid revenue growth across each of its operating segments in the second quarter of fiscal 2020.

Allscripts (MDRX) Q3 Earnings Beat Estimates, Improve Y/Y

Allscripts (MDRX) third-quarter results gain from growth in bookings and solid segmental performance. Contraction in both gross and operating margins remains a woe.

Luminex (LMNX) Reports Q3 Loss, Misses Revenue Estimates

Luminex's (LMNX) Q3 earnings benefit from higher revenues and solid performance across System Sales, Consumable Sales and Service Revenues. However, gross margin contraction remains a woe.

Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates

Myriad Genetics (MYGN) observes a decline in Hereditary Cancer, GeneSight, Vectra as well as Other testing revenues in Q1.

Henry Schein (HSIC) Q3 Earnings Top Estimates, Revenues Lag

Henry Schein (HSIC) registers solid performance across its key operating businesses in Q3.

Becton, Dickinson (BDX) Beats on Q4 Earnings and Revenues

Becton, Dickinson (BDX) gains from solid segmental contributions in Q4.

Urmimala Biswas headshot

Medical Products' Earnings Roster for Nov 5: BDX, ZBH & More

Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.

Surmodics (SRDX) Q4 Earnings and Revenues Beat Estimates

Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q4.

Bio-Rad (Bio) Q3 Earnings Beat Estimates on All-Line Growth

Growing strength in many of Bio-Rad's (Bio) key product lines across major geographic regions buoys investors' optimism on the stock.

Integer Holdings (ITGR) Beats on Q3 Earnings, Revenues Miss

Integer Holdings' (ITGR) Q3 earnings benefit from higher revenues and strong 2019 outlook.

PRA Health (PRAH) Q3 Earnings and Revenues Beat Estimates

PRA Health (PRAH) raises 2019 EPS view after a solid third-quarter show.

AMN Healthcare (AMN) Q3 Earnings and Revenues Top Estimates

Nurse and Allied Solutions segment drives AMN Healthcare's (AMN) third-quarter results.

Teleflex (TFX) Earnings and Revenues Beat Estimates in Q3

We are encouraged by Teleflex's (TFX) robust improvement in Q3 revenues on balanced growth across majority of segments and all geographies.

NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q3

We are encouraged to note that NuVasive (NUVA) witnessed solid revenue growth across its U.S. Spinal Hardware business in Q3.

Amedisys (AMED) Q3 Earnings Beat Estimates, Revenues Meet

Amedisys (AMED) continues to witness solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.

IDEXX (IDXX) Tops Q3 Earnings Estimates, Lowers EPS View

IDEXX (IDXX) impresses investors with solid third-quarter 2019 results on robust performance across all business segments.

CONMED (CNMD) Q3 Earnings and Revenues Surpass Estimates

CONMED's (CNMD) Q3 earnings gain from higher revenues, solid segmental performance and margin expansion. However, high long-term debt remains a concern.

Merit Medical (MMSI) Q3 Earnings & Revenues Miss Estimates

Merit Medical's (MMSI) Q3 earnings gain from higher revenues and solid segmental performance benefit. However, contraction in gross margin remains a concern.

PerkinElmer (PKI) Q3 Earnings Beat Estimates, Revenues Miss

PerkinElmer's (PKI) Q3 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.

ABIOMED (ABMD) Earnings Beat, Revenues Miss Estimates in Q2

Impella's solid show in Japan drives ABIOMED's (ABMD) fiscal second-quarter results.

QIAGEN (QGEN) Beats Q3 Earnings Estimates, Cuts Revenue View

We are impressed with QIAGEN's (QGEN) year-over-year growth across majority of operating segments in Q3.

Masimo (MASI) Earnings Beat Estimates in Q3, View Raised

Masimo (MASI) raises its 2019 product revenue guidance.

Urmimala Biswas headshot

Impressive Near-Term Outlook for Medical Instruments Industry

Growing medical awareness and economic prosperity enhance the uptake of medical instruments in the emerging economies.

Chemed (CHE) Q3 Earnings Surpass Estimates, Revenues Miss

Chemed (CHE) witnesses balanced segmental growth in third-quarter 2019.

McKesson (MCK) Q2 Earnings Meet Estimates, Revenues Beat

McKesson's (MCK) Q2 results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.